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Abstract
Background Sofosbuvir and ledipasvir with or without
ribavirin (RBV) regimens (SLR vs. SL) have exhibited
promising results for the treatment of patients with hep-
atitis C virus (HCV) genotype 1 infection.
Aim To comprehensively compare the efficacy and safety
of the SL and SLR regimen for the treatment of chronic
HCV genotype 1 infections.
Methods The Cochrane Library, PubMed, Web of Science,
and EMBASE databases were searched. Only RCTs that
compared the efficacy and safety of SL or SLR regimen for
the treatment of chronic HCV genotype 1 infection were
included. The primary outcome measures were the sus-
tained virological response weeks 12 (SVR12) post-treat-
ment and adverse events (AEs).
Results Seven studies comprising 2601 patients were
included. Compared with the SL regimen, SLR yielded a
similar probability of having an SVR12 (RR 1.002, 95 %
CI 0.998, 1.017, P = 0.780). Based on subgroup analyses,
the addition of RBV to the 8-week SL regimen improved
the SVR12 rate. However, the SLR regimen for 12 or
24 weeks did not show a superior SVR12 rate regardless of
treatment history and the presence or absence of cirrhosis.
The pooled incidence of AEs was higher in patients that
received the SLR treatment regimen (RR 1.140, 95 % CI
1.095, 1.187, P = 0.000).
Conclusions The 12-week or 24-week SL regimen with a
low incidence of AEs is as effective and well tolerated as
the SLR regimen for the treatment of patients with chronic
HCV genotype 1 infection.
Keywords Genotype 1 hepatitis C  Sofosbuvir 
Ledipasvir  Ribavirin  Efficacy  Safety
Introduction
Recent epidemiological data from the World Health
Organization (WHO) suggest that *130–150 million
people globally (2–3 % of the world’s population) are
infected with HCV. Individuals chronically infected with
HCV are more likely to develop liver failure, liver cir-
rhosis, liver cancer, and other serious liver complications
than uninfected individuals [1, 2]. HCV is responsible for
*15–40 % of the cases of cirrhosis and hepatic carcinoma
worldwide and is also the leading indication for liver
transplantation (LT) [3, 4]. Furthermore, HCV-related
morbidity and mortality will continue to increase over the
next few decades, even though the incidence of new HCV
infections is declining [5, 6]. Unfortunately, there are
currently no available vaccines for the prevention of HCV
infections [7]. HCV infection remains a major global health
problem, and early diagnosis and treatment are essential.
The standard of care (SOC) for the treatment of chronic
hepatitis C consists of combination therapy with weekly
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PEG-interferon (PEG-IFN) and twice-daily oral RBV (PR)
[8, 9]; however, IFN-based treatments are accompanied by
severe adverse effects, low tolerability, and a suboptimal
sustained virological response (SVR, the most important
target of a treatment for hepatitis C). Therefore, interferon-
free regimens are needed urgently [10, 11]. With the
introduction of direct-acting antiviral agents (DAAs), the
treatment of HCV infections is evolving rapidly, and
interferon-free regimens are becoming a reality. DAAs are
also associated with improved response rates and decreased
treatment therapy durations. Several RCTs have shown that
DAAs have higher SVR rates and fewer side effects than
the PR regimen, particularly for HCV genotype 1 infec-
tions [12–15]. Genotype 1 HCV is the most prevalent type
of HCV worldwide (accounting for *50 % of all HCV
infections), and it is also the most difficult to cure [1, 16].
The American Association for the Study of Liver Diseases
(AASLD) and the Infectious Diseases Society of America
(IDSA) together updated guidelines for the treatment of
HCV infection [17]. It was recommended that the treatment
of HCV infections should consist of several DAAs (el-
basvir/grazoprevir, LDV, SOF, simeprevir, daclatasvir,
ombitasvir/paritaprevir/ritonavir, dasabuvir, velpatasvir),
alone or in combination with RBV. Among the approved
DAAs, the LDV/SOF combination therapy demonstrated
excellent SVR rates in a series of related clinical trials
[18–21]. However, it is unknown whether the addition of
RBV to the LDV/SOF combination regimen improves the
efficacy further. Furthermore, the potential AEs caused by
the triple therapy are also unclear. Therefore, we performed
a meta-analysis of RCTs to evaluate the efficacy and safety
of SOF plus LDV with or without RBV in patients with
genotype 1 hepatitis C. This study provides significant
guidance to clinicians when selecting treatment strategies
for patients with genotype 1 HCV infection.
Methods
Literature Searches
Two investigators (Qiu-feng He and Qiong-fang Zhang)
performed electronic searches of the Cochrane Library,
PubMed, Web of Science, and EMBASE databases inde-
pendently between January 2015 and March 2016. The
literature searches were performed using both medical
subject heading (MeSH) terms and text words. The fol-
lowing keywords were used to identify relevant studies:
‘‘hepatitis C’’ or ‘‘HCV,’’ ‘‘genotype,’’ ‘‘ledipasvir,’’ ‘‘so-
fosbuvir,’’ and ‘‘ribavirin.’’ Furthermore, the reference
sections of all the articles identified were scanned, and any
review articles on related topics were searched manually to
identify additional potentially related studies. When
necessary, we contacted authors of the studies to obtain
further information.
Inclusion and Exclusion Criteria
Published or unpublished studies were included if they met
the following criteria: (1) They studied patients with
genotype 1 HCV infections; (2) they compared the efficacy
and safety of triple therapy (SLR) with dual therapy (SL);
(3) the main outcome measure was the sustained virolog-
ical response weeks 12 after the end of treatment (SVR12);
(4) they reported the number of patients that achieved and
failed to achieve SVR12 in each treatment group; and (5)
they were RCTs. Studies were excluded if any one of the
following occurred: (1) They included patients with non-
genotype 1 HCV infections; (2) they included patients
infected with more than one type of hepatitis virus or other
virus; (3) they failed to provide the main endpoint
(SVR12); (4) they did not report the number of patients that
achieved and failed to achieve SVR12 in each group; and
(5) they were non-randomized controlled trials.
Study Selection
First, two reviewers (QFH and QFZ) screened the title and
abstract of each article independently and identified pub-
lications potentially eligible for inclusion. After obtaining
the full text of the studies identified in the initial screen, the
same reviewers assessed the eligibility independently by
reviewing the full text. Disputes between reviewers were
resolved by consensus when possible. When required, a
third investigator (DZZ) provided arbitration.
Data Extraction
Data from all selected articles were extracted by two
investigators (QFH and QFZ) independently using a pre-
established data extraction form. The following data were
extracted: first author’s name, year of publication, study
design, country, number of patients, and the age, sex, race,
body mass index (BMI), HCV RNA levels, drug dosage,
and duration of treatment in each group. Any dispute
between the investigators was resolved as described above.
Quality Evaluation
All the studies included in the meta-analysis were assessed
for methodological quality using the Jadad score [22]. The
new Jadad score contains four rating points: randomization
(0–2 points), randomization concealment (0–2 points),
blinding (0–2 points), and a reasonable explanation of the
reasons for dropouts or withdrawals (0–1 point). Two
points were given if the literature used appropriate
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methods, one point was added if the study failed to offer a
detailed description of the methods, and no points were
gained when neither of these occurred. The quality scale
ranged from 0 (minimum) to 7 (maximum) points. A score
of four or more indicated that a study contained high-
quality research.
Outcomes
Outcomes were defined prior to study initiation. To esti-
mate the efficacy of SL treatment with or without RBV in
the included studies, SVR12 was defined as the primary
outcome. AEs were included as another main outcome to
assess the safety of the two treatment regimens. The sec-
ondary outcomes were as follows: (1) virological relapse
(post-treatment HCV RNA concentrations[25 IU/mL at
any time during follow-up after a serum HCV RNA
\25 IU/mL was recorded at the end of treatment); (2)
treatment discontinuation due to the adverse events; and (3)
five main AEs (nausea, headache, insomnia, fatigue, and
anemia).
Statistical Analyses
The efficacy and safety outcomes investigated in this study
were dichotomous variables; therefore, relative risk (RR)
and 95 % confidence intervals (CIs) were used to compare
the safety and efficacy and safety of the two treatment
regimens. Fixed-effects models were used by taking any
differences in the treatment regimens among the included
studies into account. P values and I2 indices were used to
assess heterogeneity among the different studies; P\ 0.05
and I2[ 50 % indicated significant heterogeneity. Funnel
plots were used to identify the potential presence of pub-
lication bias, and Begg’s or Egger’s weighted regression
statistics were used when necessary [23]. All analyses were
conducted using Stata (version 12.0) software.
Results
Search Results and Study Characteristics
A total of 210 potentially relevant titles and abstracts were
identified during the electronic database and manual sear-
ches. Of the 20 reports that were considered to be poten-
tially relevant, seven met the study inclusion criteria.
Thirteen potential trials were excluded for the following
reasons: six included co-infected patients, five contained
non-genotype 1 HCV infection patients, and two failed to
provide sufficient data on primary outcomes. Finally, seven
RCTs involving genotype 1 HCV infection patients were
included in the meta-analysis (Fig. 1). The resulting
analyses included 2601 participants, of which 1204 were in
the SLR therapy group. The full text of all eligible RCTs
was published between 2014 and 2015. Patients in the
included trials were from the USA, New Zealand, France,
Japan, and other countries and were aged mainly
50–60 years. The basic characteristics of the seven RCTs
included in the meta-analysis are presented in Table 1.
Quality Assessment
The methodological quality of the included trials was
assessed using the Jadad scale, and the results are shown in
Table 2. All the included studies had high methodological
quality and scored five or more points. The randomization
procedure was reported in sufficient detail to ensure that it
was appropriate in four studies, but was not reported in
three. In addition, all studies achieved a reasonable ran-
domization concealment and blinded the treatment groups
effectively. Finally, five of the seven articles reported the
number and the reasons for any dropouts or treatment
withdrawals.
SVR12 in the SL and SLR Groups
The meta-analysis of SVR12 in all patients receiving SLR
and SL therapy is shown in Fig. 2. The SVR12 in genotype
1 HCV infection patients ranged from 70 to 100 %. The
pooled data showed that there was no statistically signifi-
cant difference in the overall proportion of patients
achieving SVR12 between the two groups (RR = 1.002,
95 % CI = 0.988, 1.017, P = 0.780, I2 = 5.3 %).
Based on treatment history, the presence or absence of
cirrhosis and duration of treatment, we subsequently per-
formed subgroup analyses. Treatment-naı¨ve patients that
received the SLR and SL regimens had a similar proba-
bility of achieving SVR12 (RR = 0.994, 95 %
Fig. 1 Flowchart of the literature search and selection methods used
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CI = 0.975, 1.014, P = 0.567, I2 = 0.0 %). Similar
observations were made in previously treated patients
(RR = 1.020, 95 % CI = 0.990, 1.051, P = 0.201,
I2 = 32.6 %). As for the presence or absence of cirrhosis,
the SLR regimen did not show a superior SVR12 rate in
cirrhotic patients (RR = 1.022, 95 % CI = 0.955, 1.094,
P = 0.528, I2 = 70.9 %) or patients including those with
cirrhosis (RR = 1.003, 95 % CI = 0.990, 1.016,
P = 0.629, I2 = 0.0 %). Considering the duration of
treatment, there was no statistically significant difference
in the proportion SVR12 between the SLR and SL groups
in patients receiving 12 weeks of treatment (RR = 1.010,
95 % CI = 0.989, 1.031, P = 0.374, I2 = 59.0 %) or
patients receiving 24 weeks of treatment (RR = 1.010,
95 % CI = 0.988, 1.025, P = 0.496, I2 = 44.6 %). Only
SVR12 rate among patients who received 8 weeks of SLR
therapy was statistically superior to that among patients
who received 8 weeks of SL therapy (RR = 1.040, 95 %
CI = 1.001, 1.081, P = 0.047, I2 = 0.0 %). The data from
the subgroup analysis of treatment history, the presence or
absence of cirrhosis, and duration of treatment are pre-
sented in Table 3.
Relapse Rates in the SL and SLR Groups
Next, the relapse rates were compared in patients that
received the triple and dual therapy. Data revealed that the
relapse rates were comparable between groups
(RR = 0.746, 95 % CI = 0.441, 1.261, P = 0.274,
I2 = 30.6 %; Fig. 3).
Table 1 Main characteristics of the studies and patients enrolled in this meta-analysis


















































































Author Year Country SLR drug dosage (mg/day) Duration of treatment
(weeks)
Eric et al. [24] 2014 America SOF ? LDV ? RBV1000 (weight\ 75 kg)/1200 mg
(weight C 75 kg)
8
Edward et al. [25] 2014 New
Zealand
SOF ? LDV ? RBV1000 (weight\ 75 kg)/1200 mg
(weight C 75 kg)
12
Kris et al. [26] 2014 America SOF ? LDV ? RBV1000 (weight\ 75 kg)/1200 mg
(weight C 75 kg)
8–12
Nezam et al. [27] 2014 France SOF ? LDV ? RBV1000 (weight\75 kg)/1200 mg
(weight C 75 kg)
12–24
Nezam et al. [28] 2014 America SOF ? LDV ? RBV1000 (weight\ 75 kg)/1200 mg
(weight C 75 kg)
12–24
Marc et al. [29] 2015 France SOF ? LDV ? RBV1000 (weight\ 75 kg)/1200 mg




2015 Japan SOF ? LDV ? RBV600 (weight B 60 kg) 12
SOF ? LDV ? RBV800 (60 kg\weight B 80 kg)
SOF ? LDV ? RBV1000 (weight[ 80 kg)
SLR = SOF ? LDV ? RBV; SL = SOF ? LDV. Values denote patients in the SLR group (before slash) and those in the SL group (after
slash). Values of age, BMI, and HCV RNA presented as means. The drug dosage for SOF, 400 mg/day; and for LDV, 90 mg/day in SL and SLR
regimen
NA not available, BMI body mass index
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Table 2 Assessment of the quality of the studies included in the meta-analysis
Author Year Randomization Allocation concealment Blinding method Withdrawals Total score
A Un In A Un In A Un In Description Undescribed
Eric et al. [24] 2014 Yes Yes Yes Yes 7
Edward et al. [25] 2014 Yes Yes Yes Yes 7
Kris et al. [26] 2014 Yes Yes Yes Yes 5
Nezam et al. [27] 2014 Yes Yes Yes Yes 5
Nezam et al. [28] 2014 Yes Yes Yes Yes 6
Marc et al. [29] 2015 Yes Yes Yes Yes 7
Masashi et al. [30] 2015 Yes Yes Yes Yes 7
In the randomization, allocation concealment and blinding method, if the method adequate = 2 scores, unclear = 1 score and inadequate = 0
score
A adequate, Un unclear, In inadequate
Fig. 2 Meta-analysis
comparing the SVR12 rate
between the SLR and SL groups
Table 3 Results of subgroup
analyses evaluating the
difference in SVR12 based on
treatment history, the presence
or absence of cirrhosis, and
duration of treatment in patients
with HCV genotype 1 infection
Subgroups Number of study SLR/SL RR I2 (%) P value 95 % CI
Lower Upper
Treatment history
TN patients 671/901 0.994 0.00 0.567 0.975 1.014
PT patients 338/325 1.020 32.60 0.201 0.990 1.051
The presence or absence of cirrhosis
With cirrhosis 868/868 1.003 0.00 0.629 0.990 1.016
Cirrhosis only 80/88 1.022 70.90 0.528 0.955 1.094
Duration of treatment
8 weeks 237/451 1.040 0.00 0.047 1.001 1.081
12 weeks 540/542 1.010 59.00 0.374 0.989 1.031
24 weeks 328/326 1.010 44.60 0.496 0.988 1.025
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Treatment Safety in the SL and SLR Groups
All of the included trials reported data regarding the inci-
dence of AEs. Therefore, we conducted a meta-analysis to
investigate the incidence of AEs and the rate of discon-
tinuation due to AEs in patients receiving SLR versus SL
therapy. The pooled data showed that there was an
increased risk of AEs in the SLR group compared with the
SL group (RR = 1.140, 95 % CI = 1.095, 1.187,
P = 0.000, I2 = 0.0 %; Fig. 4). Overall, 2026 (78 %) of
2601 patients had at least one AE. The most common AEs
were nausea, headache, insomnia, fatigue, and anemia. The
addition of RBV to SL increased the incidence of drug-
related AEs, as shown in Table 4. We next analyzed the
rate of treatment discontinuation due to AEs. Surprisingly,
there was no difference in the rate of therapy discontinu-
ation due to AEs between groups (RR = 1.670, 95 %
CI = 0.666, 4.185, P = 0.274, I2 = 0.0 %; Fig. 5).
Publication Bias
Finally, we investigated the risk of publication bias in the
seven RCTs for the purpose of assessing the strength of the
evidence. A funnel plot of the standard error log RR rate
versus the RR rate was relatively symmetrical. No publi-
cation bias was identified (Fig. 6).
Discussion
The present study is the first attempt to review the literature
and provide a comprehensive comparison of the efficacy
and safety of the SL and SLR regimens for the treatment of
patients with HCV genotype 1 infections. The results
demonstrated that SVR12 and the relapse rate did not differ
significantly between the two regimens. However, the
incidence of AEs, including anemia, fatigue, headache, and
nausea, was higher in patients that received the triple
regimen compared with the dual regimen.
For over 20 years, the standard of treatment for HCV
infections, including chronic HCV genotype 1 infection,
has been the combination of PEG-IFN-a and RBV. This
traditional therapy results in a suboptimal rate of sustained
virological response (SVR) and an unfavorable AE profile
[31]. Patients with HCV genotype 1 infection experience
an even poorer outcome [32]. Although IFN-free regimens
consisting of combinations of newly approved DAAs
recently became available [33, 34], RBV continues to be
included in a number of therapeutic regimens [24–30]. The
current analysis suggests that the addition of RBV to the
SL regimen cannot improve the rate of SVR12, regardless
of the treatment history (treatment naive vs. treated pre-
viously). As for the duration of treatment, rates of SVR12
were similar in patients receiving 12 or 24 weeks of
treatment between SLR and SL groups. However, the
addition of RBV to the 8 weeks of SL regimen offered
additional benefit to the rate of SVR12. It seemed like that
the inclusion of ribavirin in the 8-week SL regimen with
better efficacy than 8-week SL regimen alone appeared to
be a more rational treatment option. With extension of the
duration to 12 or 24 weeks, no additional benefit was
associated with the inclusion of RBV in the SL regimen.
The 12-week or 24-week SL regimen alone may have
enough potential to cure most patients with HCV genotype
1 infection. Patients with cirrhosis resulting from chronic
HCV infection are at risk of life-threatening complications,
Fig. 3 Meta-analysis
comparing the relapse rate
between the SLR and SL groups
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but consistently achieve lower SVR than patients without
cirrhosis. SL plus ribavirin for 12 weeks and SL for
24 weeks provided similarly high SVR12 rates in previous
non-responders with HCV genotype 1 and compensated
cirrhosis [29]. Surprisingly, our stratified analyses based on
the presence or absence of cirrhosis demonstrated that
addition of RBV to the SL regimen did not improve the rate
of SVR12 in patients including those with cirrhosis and
Fig. 4 Meta-analysis
comparing the drug safety of the
SLR and SL groups
Table 4 Results of subgroup
analyses evaluating the rate of
AEs in patients with HCV
genotype 1 infection between
SLR and SL groups
AEs Number of study RR I2 (%) P value 95 % CI
SLR/SL Lower Upper
Nausea 194/128 1.725 0.0 0.000 1.395 2.132
Insomnia 181/96 2.075 0.0 0.000 1.639 2.627
Anemia 108/8 15.244 4.2 0.000 7.530 30.859
Headache 288/272 1.162 49.6 0.043 1.005 1.343
Fatigue 352/256 1.623 60.0 0.000 1.411 1.866
Fig. 5 Meta-analysis
comparing the treatment
discontinuation rate due to AEs
in the SL and SLR groups
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cirrhotic patients only. Among the included studies, only
one study analyzed the SVR12 in patients without cirrho-
sis. There was no significant difference in patients without
cirrhosis achieving SVR12 between SLR and SL groups
[26]. Further high-quality studies which enrolled patients
without cirrhosis are still needed to confirm these results.
The relapse rate was also comparable between treatment
groups. Therefore, the current meta-analysis provides evi-
dence that addition of RBV does not improve the efficacy of
the SL regimen for the treatment of patients with genotype 1
infection. Furthermore, it was reported previously that the
addition of RBV to SL therapy for 12 weeks or prolonging
the treatment for 24 weeks could improve the SVR12 rate
in patients with decompensated cirrhosis [35]. In contrast,
another study reported that there was no significant differ-
ence in the SVR12 rate after 12 and 24 weeks of treatment
with the SL regimen in treatment-naive genotype 1 patients,
16 % of whom were cirrhotic [27]. As the amount of lit-
erature in this area increases, we will comprehensively
evaluate whether prolonging the treatment period using the
SL regimen could improve treatment efficacy in patients
with HCV genotype 1 infection, particularly in patients that
did not achieve SVR after treatment with PEG-IFN and
RBV, and with or without a protease inhibitor.
The available safety profiles of RBV are based primarily
on the co-administration of RBV with IFN in the treatment
of HCV infection and previous RBV monotherapy [36, 37].
The current meta-analysis demonstrated that there was a
much higher risk of AEs (anemia, fatigue, headache, and
nausea) with the SLR regimen compared with the SL
regimen. Therefore, the 12-week or 24-week SL regimen
with a lower risk of AEs and similar SVR12 rate compared
to SLR regimen seemed to be a suitable therapy. Further-
more, this provides a unique opportunity to compare the
safety of an RBV-containing and an RBV-sparing regimen
in the absence of IFN. Interestingly, there was no
difference in the incidence of discontinuation due to AEs
between treatment regimens. We speculate that although
the addition of RBV to the SL regimen increases the
incidence of AEs, these tolerable side effects did not result
in a higher rate of discontinuation.
The introduction DAAs, including the SL regimen, was
an extraordinary development in the treatment of patients
with HCV. However, the very high cost of DAAs (cost per
course: SOF, $84,000; SOF plus LDV, $94,500) is always
challenging. Therefore, IFN-based therapies remain the
preferred standard treatment option for HCV-infected
patients, particularly those living in low- and middle-in-
come countries or those paying for treatment out-of-pocket
[38]. The addition of RBV to the SL regimen will further
increase the financial burden and potential AEs. Thus, the
SL regimen is more reasonable for the treatment of patients
with HCV. The current preferred IFN-based therapy
remains a suitable treatment option for HCV-infected
patients and particularly for those with favorable IFN-re-
sponse characteristics such as the IL28B genotype [39].
The current study has some limitations that must be
acknowledged. First, most of the studies included in the
analysis enrolled only non-cirrhotic patients. Thus, the
results of our analysis may not be applicable to all patients
with HCV genotype 1, particularly those with HCV-related
cirrhosis. Second, some studies included interventions with
a range of treatment doses. Unfortunately, we were unable
to perform subgroup analyses according to the drug doses
because of the small number of relevant studies identified.
Furthermore, we could not accurately evaluate treatment
efficacy, especially safety, of each regimen due to the lack
of placebo controls.
In conclusion, the SLR regimen for 12 or 24 weeks had
a similar efficacy as the SL regimen for the treatment of
patients with HCV genotype 1. Although the 8-week SLR
regimen showed superior SVR12 to the 8-week SL regi-
men, the addition of RBV to the SL regimen increased the
risk of AEs, as well as the economic burden. Therefore, the
12-week or 24-week SL regimen should be recommended
as the first-line treatment for patients with HCV genotype 1
infection, regardless of their prior treatment history and the
presence or absence of cirrhosis.
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